Last reviewed · How we verify
NCT05758701: CT TAVR
CT TAVR Abdomen Study
Phase 4 trial testing Iodinated Contrast Agent (Omnipaque) in Transcatheter Aortic Valve Replacement in 164 participants. Currently enrolling.
1 March 2027
Quick facts
| Lead sponsor | University of Maryland, Baltimore |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 164 |
| Start date | 19 September 2023 |
| Primary completion | 1 March 2027 |
| Estimated completion | 1 March 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Iodinated Contrast Agent (Omnipaque)
- Dual Energy CT
Conditions studied
- Transcatheter Aortic Valve Replacement — all drugs for Transcatheter Aortic Valve Replacement →
Sponsor
University of Maryland, Baltimore
Who can join
Adults 18 to 88, any sex, with Transcatheter Aortic Valve Replacement. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A standard polyenergetic CT (computed tomography) procedure utilizes 100 ml of iodinated contrast. A recent world-wide shortage of iodine based intravenous contrast has highlighted the need to search for alternative methods or doses. Reducing iodinated IV contrast dose can mitigate IV contrast supply shortages and enable significant cost savings for the radiology practice and hospital system. In addition, decreased IV contrast dose can potentially reduce the rate of acute kidney injury, specifically in patients with decreased renal function. The purpose of the study is to determine whether low IV contrast dose CT with monoenergetic reconstruction can be use for presurgical planning of transcatheter valve replacement (TAVR) procedure.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05758701
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Transcatheter Aortic Valve Replacement
Currently open trials in the same condition.
- NCT06559332 — Coronary Artery Disease Assessment Strategies in TAVI Patients · NA · recruiting
- NCT06896227 — TAVR: The Impact of Prothesis Positioning on Valvular and Coronary Hemodynamics · NA · recruiting
- NCT06420830 — Valve Performance of the SAPIEN 3 Ultra RESILIA Valve: A Prospective Registry With Central Echocardiography Analysis. · recruiting
- NCT06000943 — Ischemic And Bleeding Risk Assessment After TAVR · recruiting
- NCT05779787 — COronary Re-engageMent aFter randOm NavitoR alignmenT (COMFORT STUDY) · recruiting
Other University of Maryland, Baltimore trials
Trials by the same sponsor.
- NCT07537413 — Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia · Phase 4 · not yet recruiting
- NCT07221799 — OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis · Phase 1 · not yet recruiting
- NCT07094672 — Development of an Opioid Withdrawal Clinical Outcome Assessment · not yet recruiting
- NCT06583239 — Hub-Based Engagement Navigator Service to Reduce CSC Disengagement · NA · not yet recruiting
- NCT07536412 — Decision Aid Efficacy in Low Risk Thyroid Cancer · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05758701 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Maryland, Baltimore
- Last refreshed: 24 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05758701.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing